Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

BACKGROUND: The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, J, Hozak, R R, Yoshino, T, Cohn, A L, Obermannova, R, Bodoky, G, Garcia-Carbonero, R, Ciuleanu, T -E, Portnoy, D C, Prausová, J, Muro, K, Siegel, R W, Konrad, R J, Ouyang, H, Melemed, S A, Ferry, D, Nasroulah, F, Van Cutsem, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888948/
https://www.ncbi.nlm.nih.gov/pubmed/29228087
http://dx.doi.org/10.1093/annonc/mdx767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888948/
https://www.ncbi.nlm.nih.gov/pubmed/29228087
http://dx.doi.org/10.1093/annonc/mdx767

Ejemplares similares